Plus   Neg

EQT Corp. Posts Adj. Loss In Q3; Issues Preliminary 2020 Outlook

EQT Corp. (EQT) reported an adjusted loss per share from continuing operations of $0.06 for the third quarter compared to profit of $0.16 per share, prior year. Reported loss from continuing operations was $361 million, or $1.41 per share, compared to a loss from continuing operations of $127 million, or a loss of $0.49 per share, prior year.

Third quarter total operating revenues declined to $951.58 million from $1.05 billion, prior year. The company achieved sales volumes of 381 Bcfe or 4.14 Bcfe/d, for the quarter.

CEO Toby Rice said: "The execution of our planned initiatives is expected to reduce capital expenditures by approximately $525 million in 2020, as compared to prior full-year 2019 guidance."

The company's preliminary 2020 forecast is to generate between $200 and $300 million of adjusted free cash flow. The company intends to reduce absolute debt by at least $1.5 billion by mid-year 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT